Haemonetics Corp. (HAE) announced a definitive agreement under which the company would acquire Global Med for approximately $60 million in a cash tender offer. The company would fund the acquisition from available cash and anticipates that it would continue to have more than $100 million in cash on the balance sheet at fiscal year end.
As per the terms of the deal, Haemonetics would begin a tender offer to buy all outstanding shares of Global Med's common stock at $1.22 per share and preferred stock at about $1,694 per share. Haemonetics expects the transaction to close in its fourth quarter fiscal 2010.
Additionally, the company tightened its fiscal 2010 guidance ranges to 8% - 9% revenue growth from 8% - 11% and earnings per share in a range of $2.80 - $2.85 compared with its prior range of $2.75 - $2.85. On average, 12 analysts polled by Thomson Reuters expected earnings per share of $2.82 for the quarter. Analysts' estimate typically excludes one-time items.
For comments and feedback contact: editorial@rttnews.com
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.